Oral Cannabis Dosage Forms

Quality, formulation and manufacturing considerations for capsules, oral liquids and oromucosal products.

1 min read · Last reviewed: July 2026 · European Cannabis Institute Editorial Team

Explore this Phase 3 topic

This hub connects focused technical articles with ECI's existing knowledge, quality and professional-development content.

References

  • Ph. Eur. — Oral Dosage Forms, General Monographs
  • ICH Q6A — Specifications for New Drug Substances and Products
  • EMA Guideline on Pharmaceutical Development of Medicines for Paediatric Use (excipient reference)

Confirm the current effective version and national applicability before operational, regulatory or clinical use.

Use the knowledge in practice

Apply these principles through ECI training, assessment tools and specialist consultancy support.

Related reading

Article
Compressed Gases in Cannabis GMP Manufacturing
Article
Medical Cannabis Dosage Forms
Article
Residual Solvent Testing in Cannabis Extracts
Article
Oromucosal Cannabis Sprays: Formulation and Device Quality
Article
Solvent Recovery Systems in Cannabis Manufacturing

Frequently asked questions

What is the main quality objective for oral cannabis dosage forms?

The objective is to define and maintain controls that ensure identity, consistency, safety and fitness for the intended use.

Which regulatory framework applies?

The applicable framework depends on jurisdiction, intended use, product classification and lifecycle stage. EU GMP, pharmacopoeial and product-specific requirements may all be relevant.

Is finished-product testing sufficient?

No. Testing is only one element of assurance. Supplier controls, process understanding, qualification, in-process monitoring and data governance are also required.

How should specifications be set?

Specifications should be scientifically justified using process capability, safety considerations, stability data, pharmacopoeial requirements and the intended clinical or technical use.

Why is trending important?

Trending can reveal gradual drift, supplier changes or method deterioration before individual results breach an acceptance limit.